Applied DNA Sciences Inc., of Stony Brook, N.Y., is set to join the Russell Microcap Index, effective when the U.S. market opens on June 29, 2020.
The Biocodex Microbiota Foundation, an organization founded by Biocodex Inc., of San Mateo, Calif., has issued a call for applications for its annual U.S. research grant to a U.S.-based, early-career investigator. The theme for this year’s $50,000 award is gut microbiota and chronic disease. The deadline for entry is Oct. 15, 2020.
Pompano Beach, Fla.-based Biostem Technologies Inc. said its subsidiary, Biostem Life Sciences, has achieved tissue bank certification in California and Maryland.
Munich-based digital health company Brainlab AG has formed a new subsidiary, Snke Os, with 65 employees from Brainlab and plans to fill 100 new positions. The move allows Snke Os to market to a wider circle of industry startups, partners and competitors, Brainlab said. The team is currently developing a digital surgical platform, using Brainlab software.
Intersect ENT Inc., of Menlo Park, Calif., reported independent results from a U.K.-based study confirming the cost-effectiveness of its Propel steroid-releasing sinus implant following surgery for chronic sinusitis. According to the Device Access UK analysis, inserting the bioabsorbable corticosteroid-eluting sinus implant (CESI) at the end of functional endoscopic sinus surgery was less costly than a non-corticosteroid-eluting spacer for FESS by a difference of £4,646 to £4,655 (US$5,732 to $5,744) per patient, and demonstrated higher total quality-adjusted life years over six months (0.443 vs. 0.444). The probabilistic analysis concluded that CESI following FESS “has a 62% probability of being cost effective at the £20,000/per QALY willingness-to-pay threshold and a 56% probability of being a cost-saving intervention.”
Helsinki-based Nexstim plc said it received two NBS (navigated brain stimulation) system update orders from a German and Swedish university hospital. The orders involve upgrading the Nexstim NBS system to the latest Smartfocus nTMS (navigated transcranial magnetic stimulation) features that will replace the hospitals’ older Nexstim platform.
Phunware Inc., of Austin, reported a joint venture with Anyplace MD, of Cedar Park, Texas, to provide an end-to-end COVID-19 solution, including contact tracing, telehealth, testing and logistics support to government agencies and health systems.
Toronto-based Venus Concept Inc. said it has been added to the Russell 2000, Russell 3000 and Russell Microcap Indexes, effective after the U.S. market closes on June 26, 2020.